Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Antisense oligonucleotides (ASOs) are most commonly designed to reduce targeted RNA via RNase H1-dependent degradation. In this paper we demonstrate that cellular proteins can compete for sites targeted by RNase H1-dependent ASOs. We further show that some ASOs designed to mediate RNase H1 cleavage can, in certain instances, promote target reduction both by RNase H1-mediated cleavage and by steric inhibition of binding of splicing factors at a site required for efficient processing of the pre-mRNA. In the latter case, RNase H cleavage was prevented by binding of a second protein, HSPA8, to the ASO/pre-mRNA heteroduplex. In addition, using a precisely controlled minigene system, we directly demonstrated that activity of ASOs targeting sites in introns is strongly influenced by splicing efficiency.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191969 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0108625 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Antisense oligonucleotides targeting the SARS-CoV-2 nucleocapsid gene decrease viral titers in hamsters.
Mol Ther Nucleic Acids
September 2025
Université Paris-Saclay, AgroParisTech, INRAE, GABI UMR1313, 78350 Jouy-en-Josas, France.
SARS-CoV-2 is a positive, single-stranded RNA coronavirus responsible for the COVID-19 pandemic. The emergence of new variants and the limited efficacy of current antivirals demonstrate the need for novel therapeutic strategies. Here, we present the design, screening, and evaluation of antisense oligonucleotides (ASOs) targeting the SARS-CoV-2 genomic and sub-genomic RNA.
View Article and Find Full Text PDFGOLGA8 increases bulk antisense oligonucleotide uptake and activity in mammalian cells.
Mol Ther Nucleic Acids
June 2023
Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA.
Antisense oligonucleotides (ASOs) are short synthetic nucleic acids that recognize and bind to complementary RNA to modulate gene expression. It is well established that single-stranded, phosphorothioate-modified ASOs enter cells independent of carrier molecules, primarily via endocytic pathways, but that only a small portion of internalized ASO is released into the cytosol and/or nucleus, rendering the majority of ASO inaccessible to the targeted RNA. Identifying pathways that can increase the available ASO pool is valuable as a research tool and therapeutically.
View Article and Find Full Text PDFNAT10 and DDX21 Proteins Interact with RNase H1 and Affect the Performance of Phosphorothioate Oligonucleotides.
Nucleic Acid Ther
August 2022
Department of Core Antisense Research, Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.
RNase H1-dependent phosphorothioate oligonucleotides (PS-ASOs) have been developed to treat various diseases through specific degradation of target RNAs. Although many factors or features of RNA and PS-ASOs have been demonstrated to affect antisense activity of PS-ASOs, little is known regarding the roles of RNase H1-associated proteins in PS-ASO performance. In this study, we report that two nucleolar proteins, NAT10 and DDX21, interact with RNase H1 and affect the potency and safety of PS-ASOs.
View Article and Find Full Text PDFEmerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases.
J Neuromuscul Dis
February 2022
Department of Paediatrics, University of Oxford, Oxford, UK.
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition.
View Article and Find Full Text PDFBinding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins.
Nucleic Acids Res
March 2021
Core Antisense Research, Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA.
We recently found that toxic PS-ASOs can cause P54nrb and PSF nucleolar mislocalization in an RNase H1-dependent manner. To better understand the underlying mechanisms of these observations, here we utilize different biochemical approaches to demonstrate that PS-ASO binding can alter the conformations of the bound proteins, as illustrated using recombinant RNase H1, P54nrb, PSF proteins and various isolated domains. While, in general, binding of PS-ASOs or ASO/RNA duplexes stabilizes the conformations of these proteins, PS-ASO binding may also cause the unfolding of RNase H1, including both the hybrid binding domain and the catalytic domain.
View Article and Find Full Text PDF